4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · IEX Real-Time Price · USD
24.07
+0.78 (3.35%)
At close: Jun 12, 2024, 4:00 PM
24.04
-0.03 (-0.12%)
After-hours: Jun 12, 2024, 5:04 PM EDT

4D Molecular Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019 2018
Revenue
20.723.1318.0413.616.99
Upgrade
Revenue Growth (YoY)
562.29%-82.65%32.52%94.85%-50.56%
Upgrade
Gross Profit
20.723.1318.0413.616.99
Upgrade
Selling, General & Admin
36.4932.9128.0117.2413.9
Upgrade
Research & Development
97.180.2561.3653.0438.72
Upgrade
Other Operating Expenses
00005.14
Upgrade
Operating Expenses
133.59113.1689.3770.2857.75
Upgrade
Operating Income
-112.87-110.03-71.33-56.66-50.76
Upgrade
Other Expense / Income
-12.03-2.54-0.020.03-1.46
Upgrade
Pretax Income
-100.84-107.49-71.32-56.69-49.31
Upgrade
Net Income
-100.84-107.49-71.32-56.69-49.31
Upgrade
Shares Outstanding (Basic)
39322865
Upgrade
Shares Outstanding (Diluted)
39322865
Upgrade
Shares Change
20.95%16.66%331.23%25.05%1.85%
Upgrade
EPS (Basic)
-2.58-3.32-2.57-8.82-9.59
Upgrade
EPS (Diluted)
-2.58-3.32-2.57-8.82-9.59
Upgrade
Free Cash Flow
-78.56-98.22-78.24-51.91-39.91
Upgrade
Free Cash Flow Per Share
-2.01-3.04-2.82-8.07-7.76
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
-544.65%-3516.52%-395.46%-416.28%-726.65%
Upgrade
Profit Margin
-486.59%-3435.41%-395.37%-416.49%-705.78%
Upgrade
Free Cash Flow Margin
-379.11%-3139.05%-433.77%-381.35%-571.34%
Upgrade
EBITDA
-95.09-103.61-68.3-55.25-48.3
Upgrade
EBITDA Margin
-458.85%-3311.41%-378.63%-405.89%-691.41%
Upgrade
Depreciation & Amortization
5.753.883.021.441
Upgrade
EBIT
-100.84-107.49-71.32-56.69-49.31
Upgrade
EBIT Margin
-486.59%-3435.41%-395.37%-416.49%-705.78%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).